Improving the comparability of immunoassays for prostate-specific antigen (PSA): Progress and problems

Clinica Chimica Acta

Volumn 381, Issue 1, 2007, Pages 85-92

  Sturgeon, Catharine M ^a   Ellis, Andrew R ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Between method agreement; EQA; Equimolarity; Free PSA; Method comparability; PSA; Standardization

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CALIBRATION; CANCER DIAGNOSIS; CANCER SCREENING; CATHETERIZATION; COMPARATIVE STUDY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; HUMAN; IMMUNOASSAY; LABORATORY DIAGNOSIS; MASSAGE; METHODOLOGY; MONITORING; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATITIS; REVIEW; SCREENING; STANDARDIZATION; TRANSURETHRAL RESECTION; URINARY TRACT INFECTION; URINE RETENTION;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; IMMUNOASSAY; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 34248157327     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.02.015     Document Type: Review

References (47)

1. Miller W.G., Myers G.L., and Rej R. Why commutability matters. Clin Chem 52 (2006) 553-554
2. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85 (2000) 526-529
3. Cantor T., Yang Z., Caraiani N., and Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 52 (2006) 1771-1776
4. Sturgeon C.M., and Seth J. Why do immunoassays for tumor markers give differing results?-a view from the UK National External Quality Assessment Schemes. Eur J Clin Chem Clin Biochem 34 (1996) 755-759
5. Rustin G.J., Bast Jr. R.C., Kelloff G.J., et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res 10 (2004) 3919-3926
6. Roddam A.W., Rimmer J., Nickerson C., and Ward A.M. Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England. Ann Clin Biochem 43 (2006) 35-48
7. Ward A.M., Catto J.W., and Hamdy F.C. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 38 (2001) 633-651
8. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 (1991) 222-226
9. Semjonow A., Oberpenning F., Weining C., et al. Do modifications of nonequimolar assays for total prostate-specific antigen improve detection of prostate cancer?. Clin Chem 47 (2001) 1472-1475
10. Finne P., Finne R., Bangma C., et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111 (2004) 310-315
11. Price C.P., Allard J., Davies G., et al. Pre- and post-analytical factors that may influence use of serum prostate specific antigen and its isoforms in a screening programme for prostate cancer. Ann Clin Biochem 38 (2001) 188-216
12. Sturgeon C. Quality assurance of PSA testing. In: Schmeller N. (Ed). Clinical value of PSA (2006), UNI-MED Verlag AG, Bremen 28-41 Vol.
13. Ulmert D., Becker C., Nilsson J.A., et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at - 20 degrees C. Clin Chem 52 (2006) 235-239
14. Semjonow A., Brandt B., Oberpenning F., Roth S., and Hertle L. Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values. Prostate Suppl 7 (1996) 3-16
15. White P. Annual Review: UK NEQAS for PSA. http://www.immqas.org.uk/. Accessed 24th January 2007.
16. Roddam A.W., Price C.P., Allen N.E., and Ward A.M. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom. Clin Chem 50 (2004) 1012-1016
17. Melia J., Moss S., and Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int 94 (2004) 51-56
18. Klee G. A conceptual model for establishing tolerance limits for analytic bias and imprecision based on variations in population test distributions. Clin Chim Acta 260 (1997) 175-188
19. Sturgeon C, Hammond E, Ch'ng S-L, Soletormos G, Hayes DF. National Academy of Clinical Biochemistry: Draft guidelines on quality requirements for the use of tumor markers. http://www.aacc.org/AACC/members/nacb/lMPG/OnlineGuide/DraftGuidelines/TumorMarkers/. Accessed 27th January 2007.
20. Rafferty B., Rigsby P., Rose M., Stamey T., and Gaines Das R. Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 46 (2000) 1310-1317
21. Ekins R. Measurement of free hormones in blood. Endocr Rev 11 (1990) 5-46
22. Sturgeon C.M., and Ellis A.R. Standardization of FSH, LH and hCG-current position and future prospects. Mol Cell Endocrinol 260-262 (2007) 301-309
23. Mikolajczyk S.D., Song Y., Wong J.R., Matson R.S., and Rittenhouse H.G. Are multiple markers the future of prostate cancer diagnostics?. Clin Biochem 37 (2004) 519-528
24. Chan D.W., and Sokoll L.J. WHO First International Standards for prostate-specific antigen: the beginning of the end for assay discrepancies?. Clin Chem 46 (2000) 1291-1292
25. Oberpenning F., Weining C., Brandt B., et al. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer. Clin Chem Lab Med 41 (2003) 90-94
26. Onur R., Ilhan N., and Orhan I. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. World J Urol 21 (2003) 43-47
27. Petersen P.H., de Verdier C.H., Groth T., Fraser C.G., Blaabjerg O., and Horder M. The influence of analytical bias on diagnostic misclassifications. Clin Chim Acta 260 (1997) 189-206
28. Stephan C., and Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples-a response to AW Roddam et al. Ann Clin Biochem 43 (2006) 35-48
29. Ann Clin Biochem 43 (2006) 421-422 [author reply 422-423]
30. Schreiber W.E., Endres D.B., McDowell G.A., et al. Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. Arch Pathol Lab Med 129 (2005) 331-337
31. Roddam A.W., and Milford Ward A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples-a response to AW Roddam et al. Ann Clin Biochem 43 (2006) 35-48 [Author's response]
32. Ann Clin Biochem 43 (2006) [Author reply 422-423]
33. Ishibashi M. Standardization of prostate-specific antigen (PSA) assays: can interchangeability of PSA measurements be improved?. Clin Chem 52 (2006) 1-2
34. Kort S.A., Martens F., Vanpoucke H., van Duijnhoven H.L., and Blankenstein M.A. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem 52 (2006) 1568-1574
35. Stephan C., Klaas M., Muller C., Schnorr D., Loening S.A., and Jung K. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. Clin Chem 52 (2006) 59-64
36. Stephan C., and Semjonow A. Accuracy assessment of PSA methods must be based on clinical instead of artificial samples-a response to AW Roddam et al. Ann Clin Biochem 43 (2006) 35-48
37. Ann Clin Biochem 43 (2006) 421-422
38. Dorizzi R.M., Meneghelli S., Rizzotti P., and Giavarina D. Differences of prostate-specific antigen assays: a small light at the end of the tunnel?. Ann Clin Biochem 43 (2006) 420-421 [author reply 422-423]
39. Stenman U.H., Paus E., Allard W.J., et al. Summary report of the TD-3 workshop: characterization of 83 antibodies against prostate-specific antigen. Tumor Biol 20 Suppl 1 (1999) 1-12
40. Steuber T., Vickers A., Haese A., et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007)
41. Berger P., Sturgeon C., Bidart J.M., et al. The ISOBM TD-7 Workshop on hCG and related molecules. Towards user-oriented standardization of pregnancy and tumor diagnosis: assignment of epitopes to the 3-dimensional structure of diagnostically and commercially relevant monoclonal antibodies directed against human chorionic gonadotropin and derivatives. Tumor Biol 23 (2002) 1-38
42. Satterfield M.B., and Welch M.J. Comparison by LC-MS and MALDI-MS of prostate-specific antigen from five commercial sources with certified reference material 613. Clin Biochem 38 (2005) 166-174
43. Bucknall M., Fung K.Y., and Duncan M.W. Practical quantitative biomedical applications of MALDI-TOF mass spectrometry. J Am Soc Mass Spectrom 13 (2002) 1015-1027
44. Bjerner J., Bormer O.P., and Nustad K. The war on heterophilic antibody interference. Clin Chem 51 (2005) 9-11
45. Soletormos G., Semjonow A., Sibley P.E., et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 51 (2005) 1342-1351
46. Singh R., Cahill D., Popert R., and O'Brien T.S. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int 92 (2003) 932-935
47. Wians Jr. F.H., Cheli C.D., Balko J.A., Bruzek D.J., Chan D.W., and Sokoll L.J. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer. Clin Chim Acta 326 (2002) 81-95